These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22122459)

  • 1. PPAR-γ agonists in polycystic kidney disease with frequent development of cardiovascular disorders.
    Nagao S; Yamaguchi T
    Curr Mol Pharmacol; 2012 Jun; 5(2):292-300. PubMed ID: 22122459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
    Yoshihara D; Kurahashi H; Morita M; Kugita M; Hiki Y; Aukema HM; Yamaguchi T; Calvet JP; Wallace DP; Nagao S
    Am J Physiol Renal Physiol; 2011 Feb; 300(2):F465-74. PubMed ID: 21147840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone inhibits insulin-like growth factor‑1-induced polycystic kidney disease cell growth and p70S6 kinase activation.
    Liu C; Zhang Y; Yuan L; Fu L; Mei C
    Mol Med Rep; 2013 Sep; 8(3):861-4. PubMed ID: 23864113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats.
    Dai B; Liu Y; Mei C; Fu L; Xiong X; Zhang Y; Shen X; Hua Z
    Clin Sci (Lond); 2010 Jul; 119(8):323-33. PubMed ID: 20507283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycystic kidney disease: etiology, pathogenesis, and treatment.
    Martinez JR; Grantham JJ
    Dis Mon; 1995 Nov; 41(11):693-765. PubMed ID: 7587886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
    Yoshihara D; Kugita M; Sasaki M; Horie S; Nakanishi K; Abe T; Aukema HM; Yamaguchi T; Nagao S
    PLoS One; 2013; 8(12):e81480. PubMed ID: 24324698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
    Derosa G; Maffioli P
    Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal tubular epithelium-targeted peroxisome proliferator-activated receptor-γ maintains the epithelial phenotype and antagonizes renal fibrogenesis.
    Zhao M; Chen Y; Ding G; Xu Y; Bai M; Zhang Y; Jia Z; Huang S; Zhang A
    Oncotarget; 2016 Oct; 7(40):64690-64701. PubMed ID: 27602490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor-γ agonist pioglitazone fails to attenuate renal fibrosis caused by unilateral ureteral obstruction in mice.
    Zhang Y; Wang J; Zhou QD; Zhang CH; Li Q; Huang S; Zhan J; Wang K; Liu YY; Xu G
    J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):41-47. PubMed ID: 26838738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease.
    Lager DJ; Qian Q; Bengal RJ; Ishibashi M; Torres VE
    Kidney Int; 2001 Jan; 59(1):126-36. PubMed ID: 11135065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Animal models for human polycystic kidney disease.
    Nagao S; Kugita M; Yoshihara D; Yamaguchi T
    Exp Anim; 2012; 61(5):477-88. PubMed ID: 23095811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia reduces the expression and anti-inflammatory effects of peroxisome proliferator-activated receptor-gamma in human proximal renal tubular cells.
    Li X; Kimura H; Hirota K; Sugimoto H; Kimura N; Takahashi N; Fujii H; Yoshida H
    Nephrol Dial Transplant; 2007 Apr; 22(4):1041-51. PubMed ID: 17255125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of peroxisome-proliferator-activating receptor gamma agonists: rosiglitazone and 15-deoxy-delta12,14-prostaglandin J2 in chronic experimental cyclosporine A-induced nephrotoxicity.
    Korolczuk A; Maciejewski M; Smolen A; Dudka J; Czechowska G; Widelska I
    J Physiol Pharmacol; 2014 Dec; 65(6):867-76. PubMed ID: 25554991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells.
    Yamaguchi T; Hempson SJ; Reif GA; Hedge AM; Wallace DP
    J Am Soc Nephrol; 2006 Jan; 17(1):178-87. PubMed ID: 16319189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases.
    Yang J; Zhou Y; Guan Y
    Curr Opin Nephrol Hypertens; 2012 Jan; 21(1):97-105. PubMed ID: 22143250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.
    Thiemermann C
    Br J Pharmacol; 2004 Jul; 142(6):1049-51. PubMed ID: 15303252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor gamma agonists in kidney disease--future promise, present fears.
    Mao Z; Ong AC
    Nephron Clin Pract; 2009; 112(4):c230-41. PubMed ID: 19546582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone.
    Benigni A; Zoja C; Tomasoni S; Campana M; Corna D; Zanchi C; Gagliardini E; Garofano E; Rottoli D; Ito T; Remuzzi G
    J Am Soc Nephrol; 2006 Jun; 17(6):1624-32. PubMed ID: 16687628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.
    Holditch SJ; Schreiber CA; Harris PC; LaRusso NF; Ramirez-Alvarado M; Cataliotti A; Torres VE; Ikeda Y
    Kidney Int; 2017 Sep; 92(3):657-668. PubMed ID: 28416225
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.